Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

NCT01121588

TerminatedPhase 1

Sponsor: Pfizer

Conditions: Neoplasms Malignant

Interventions: Crizotinib

Countries: United States, China, Italy, Japan, Russia, South Korea, Taiwan

This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.

Eligibility overview

Sex: ALL

Age: 15 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* histologically or cytologically proven diagnosis of malignancy other than NSCLC
* positive for translocation or inversion event involving the ALK gene locus
* positive for ALK amplification events
* positive for ALK activating point mutations

Exclusion Criteria:

* mutations of amplifications involving the c-Met gene but not the ALK gene
* concurrent treatment on another therapeutic clinical trial
* prior therapy specifically directed against ALK
Locations (21)
  • Fayetteville, Arkansas, United States
  • Rogers, Arkansas, United States
  • Springdale, Arkansas, United States
  • St Louis, Missouri, United States
  • Las Vegas, Nevada, United States
  • Portland, Oregon, United States
  • Portland, Oregon, United States
  • Portland, Oregon, United States
  • Greenville, South Carolina, United States
  • Beijing, Chaoyang District, China
  • Guangzhou, Guangdong, China
  • Monza, Italy
  • Monza, Italy
  • Nagoya, Aichi-ken, Japan
  • Chuo-ku, Tokyo, Japan
  • Fukuoka, Japan
  • Saint Petersburg, Russia
  • Saint Petersburg, Russia
  • Seoul, South Korea
  • Seoul, South Korea
  • Taipei, Taiwan